Compare Illumina, Inc. (ILMN) vs uniQure N.V. Ordinary Shares (QURE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs uniQure N.V. Ordinary Shares — how do they compare? Illumina, Inc. trades at $271.76 (market cap $41.04B), while uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B). The key difference: Illumina, Inc. is far larger — about 28.3× uniQure N.V. Ordinary Shares's market cap, and Illumina, Inc. is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 84 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ILMN | QURE | |
|---|---|---|
Market Cap | $41.04B | $1.45B |
Volume | 2,120,523 | 3,323,243 |
Sector | Health | Health |
52-Week High | $293.69 | $70.59 |
52-Week Low | $93.00 | $9.03 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $42.39B | $707.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.18, down 1.99% but near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Revenue remains stable at $4.3B with impressive profitability metrics including 66.4% gross margin and 18.3% net income margin. Recent news highlights S&P 500 inclusion and AI-driven growth initiatives.
ILMN presents a mixed outlook with strong fundamentals and technical momentum offset by premium valuations (P/E 50.6). The primary opportunity lies in genomic sequencing leadership and AI integration, while risks include valuation sensitivity and competitive pressures. Analyst consensus leans bullish with 54% buy ratings but a $241 price target suggests limited upside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →
